Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03620890 · ClinicalTrials.gov registry record · Phase 4
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
A Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 4
- Development phase
- 108
- Enrollment target
NCT03620890 is a Phase 4 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 108 participants.
The verdict
NCT03620890, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 108 participants
- Enrollment target
Study Summary
To determine whether use of detemir compared to neutral protamine hagedorn (NPH) decreases rates of composite neonatal outcome and maternal hypoglycemia events in women with Type 2 Diabetes Mellitus (T2DM).
Interventions
- DRUG Neutral Protamine Hagedorn (NPH)
- DRUG Detemir insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2018-09-04 |
| Est. Completion | 2020-07-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03620890
The ClinicalTrials.gov registry entry for NCT03620890 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Neutral Protamine Hagedorn (NPH) is the first listed.
NCT03620890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03620890 about?
NCT03620890 is a clinical study titled "Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy". To determine whether use of detemir compared to neutral protamine hagedorn (NPH) decreases rates of composite neonatal outcome and maternal hypoglycemia events in women with Type 2 Diabetes Mellitus (T2DM).
What is the current status of trial NCT03620890?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 108 participants. The study started on 2018-09-04. Estimated completion is 2020-07-29.
What interventions are being tested in trial NCT03620890?
The interventions under investigation include: Neutral Protamine Hagedorn (NPH) (DRUG), Detemir insulin (DRUG).
Who is sponsoring clinical trial NCT03620890?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.